Last reviewed · How we verify
Changchun BCHT Biotechnology Co. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
3 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Herpes Zoster Vaccine, Live | Herpes Zoster Vaccine, Live | marketed | Live attenuated vaccine | Immunology / Infectious Disease | ||
| DTacP | DTacP | phase 3 | Immunotoxin | Oncology | ||
| live attenuated zoster vaccine | live attenuated zoster vaccine | phase 3 | Immunology | |||
| DTacP-IPV/Hib | DTacP-IPV/Hib | phase 3 | Combination vaccine | Immunology / Infectious Disease Prevention |
Therapeutic area mix
- Immunology · 1
- Immunology / Infectious Disease · 1
- Immunology / Infectious Disease Prevention · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- PT Bio Farma · 2 shared drug classes
- Serum Institute of India Pvt. Ltd. · 2 shared drug classes
- Jiangsu Province Centers for Disease Control and Prevention · 2 shared drug classes
- Merck Sharp & Dohme LLC · 2 shared drug classes
- Sanofi · 2 shared drug classes
- Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Sinovac Biotech Co., Ltd · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Changchun BCHT Biotechnology Co.:
- Changchun BCHT Biotechnology Co. pipeline updates — RSS
- Changchun BCHT Biotechnology Co. pipeline updates — Atom
- Changchun BCHT Biotechnology Co. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Changchun BCHT Biotechnology Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/changchun-bcht-biotechnology-co. Accessed 2026-05-16.